In the News
Please find below a selection of recent media coverage in which the Emergex Vaccines story is featured.
Citeline SCRIP Commercial with Alaric DeArment – Emergex Goes to Battle Against ‘The Nasties’
3 May 2024
Genetic Engineering and Biotechnology News (GEN) with Uduak Thomas – ‘Vaccine Developers Leverage mRNA and Other Powerful Technologies’
1 May 2024
Progress, Potential, and Possibilities podcast episode featuring Emergex Co-Founder and CEO, Professor Thomas Rademacher, hosted by Ira Pastor.
17 April 2024
Life Science Success podcast episode featuring Emergex Co-Founder and CEO, Professor Thomas Rademacher, hosted by Don Davis, PhD.
3 February 2024
The Bio Report Podcast with Danny Levine featuring Emergex Co-Founder and CEO, Professor Thomas Rademacher – ‘Building Better and More Affordable Vaccines’
01 November 2023
BioProcess International with Millie Nelson - ‘Emergex inks deal with VIC to bolster Saudi Arabia healthcare accessibility’
18 October 2023
Pharmaceutical Technology with Phalguni Deswal – ‘Emergex and VIC to develop infectious disease therapies in the Gulf’
06 October 2023
Citeline SCRIP Commercial with Vibha Ravi – ‘Emergex CEO Questions mRNA Vaccines Against ‘Wuhan Virus,’ Works on Universal Vaccines’
31 August 2023
European Pharmaceutical Review: Anatomy of a ‘correlate of protection’ for T-cell vaccines
16 June 2022
NanoPass’s intradermal delivery platform used in Emergex’s next generation COVID-19 vaccination study
26 January 2022
The Guardian - UK firm to trial T-cell Covid vaccine that could give longer immunity
15 November 2021
CNBC news interview with Emergex Vaccines CEO, Professor Thomas Rademacher
14 May 2018
